{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:53:25Z","timestamp":1773388405954,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T00:00:00Z","timestamp":1309996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is no effective therapy for human T\u2010cell lymphotropic virus type I (HTLV\u2010I)\u2010associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Glucocorticoids are effective to reduce the motor disability in these patients, but its role as anti\u2010spastic drugs is unknown. Here it is reported the use of corticosteroids in HAM\/TSP. The goal was to find reliable molecular markers linked to treatment effectiveness. The clinical efficacy of corticosteroids was studied in 22 HAM\/TSP. The treatment was a single dose of 7.0\u2009mg of systemic betamethasone. Pre\u2010treatment samples were obtained immediately before steroid administration and post\u2010treatment samples were collected after 5 days. Neurological disability was evaluated by the Osame's Motor Disability Scales. Relative levels of Tax, Foxp3, IL\u201010, TGF\u2010\u03b2, CTLA\u20104, and GITR mRNA were measured and the percentage of CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup> and CD4<jats:sup>+<\/jats:sup>Tax<jats:sup>+<\/jats:sup> populations was quantified in PBMCs by real\u2010time PCR and flow cytometry, respectively. The same parameters were studied in eight untreated carriers. Betamethasone treatment showed neurological improvement in 21 HAM\/TSP patients, with one patient without response to treatment. This therapy was associated with a decrease in Tax mRNA load and CD4<jats:sup>+<\/jats:sup>Tax<jats:sup>+<\/jats:sup> T cells in HAM\/TSP. Simultaneously, an increase in Foxp3 mRNA and CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup> T cell was detected in these patients. The other markers studied had no significant changes after treatment. Clinical improvement in betamethasone\u2010treated HAM\/TSP was associated with an inverse relationship between a decrease in Tax and an increase in Foxp3 at the mRNA and protein levels. These results suggest that both Tax and Foxp3 may represent potential biomarkers for drug treatment assessments in HAM\/TSP. J. Med. Virol. 83:1641\u20131649, 2011. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jmv.22131","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T17:52:33Z","timestamp":1310061153000},"page":"1641-1649","source":"Crossref","is-referenced-by-count":8,"title":["Molecular and clinical effects of betamethasone in human t\u2010cell lymphotropic virus type\u2010i\u2010associated myelopathy\/tropical spastic paraparesis patients"],"prefix":"10.1002","volume":"83","author":[{"given":"Carolina","family":"Alberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuetsu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)00266-Q"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-6-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2008.01090.x"},{"key":"e_1_2_6_5_1","first-page":"101","volume-title":"Retrovirus linfotropos humanos: Aspectos epidemiol\u00f3gicos y clinicos de la infecci\u00f3n por HTLV\u2010I\/II","author":"Cartier L","year":"1998"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.2.316"},{"key":"e_1_2_6_7_1","first-page":"188","article-title":"M\u00e9todo cl\u00ednico de evaluaci\u00f3n de la espasticidad en pacientes tratados con prednisona como miorrelajante","volume":"35","author":"Cartier L","year":"1977","journal-title":"Rev Neurocirug\u00eda"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199704000-00009"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872007000900007"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2000001200001"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.01.004"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(03)00219-4"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.02.007"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0376"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/423957"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020033"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123430"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1023-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.1016"},{"key":"e_1_2_6_20_1","first-page":"1096","article-title":"The risk of development of HTLV\u2010I\u2010associated myelopathy\/tropical spastic paraparesis among persons infected with HTLV\u2010I","volume":"3","author":"Kaplan JE","year":"1990","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.014"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(91)90192-A"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315327"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/019131299281653"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90525-9"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200106000-00019"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/13550289509111010"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/13550289609146899"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2008.03.008"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/503874"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91298-5"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838168"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/380101"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-40"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-3-63"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-118539"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.15"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70081-6"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.88"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032042"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23913"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.22131","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.22131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:32:06Z","timestamp":1696912326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.22131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,7]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/jmv.22131"],"URL":"https:\/\/doi.org\/10.1002\/jmv.22131","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,7]]}}}